LRG1 is a novel HER3 ligand to promote growth in colorectal cancer
暂无分享,去创建一个
Daniel R. Martin | M. Miyagi | Derek J. Taylor | Zhenghe Wang | Yamu Li | M. Rathore | Michel’le Wright | Rui Wang | Wei-Ren Huang | Jordan R. Winter | Hao Feng | J. Greenwood | Stephen E. Moss | Lee M Elis | Moeez Rathore
[1] Rui Wang,et al. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic ductal adenocarcinoma , 2022, bioRxiv.
[2] L. Ellis,et al. Liver Endothelium Promotes HER3-mediated Cell Survival in Colorectal Cancer with Wild-type and Mutant KRAS. , 2022, Molecular cancer research : MCR.
[3] S. Moss,et al. LRG1: an emerging player in disease pathogenesis , 2022, Journal of biomedical science.
[4] S. Moss,et al. LRG1 as a novel therapeutic target in eye disease , 2022, Eye.
[5] E. Van Cutsem,et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Shubhada R. Kulkarni,et al. Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis , 2021, Science Translational Medicine.
[7] W. Wahli,et al. LRG1 Promotes Metastatic Dissemination of Melanoma through Regulating EGFR/STAT3 Signalling , 2021, Cancers.
[8] Shubhada R. Kulkarni,et al. A spatial vascular transcriptomic, proteomic, and phosphoproteomic atlas unveils an angiocrine Tie–Wnt signaling axis in the liver , 2021, Developmental cell.
[9] P. Jänne,et al. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions , 2021, Clinical Cancer Research.
[10] R. Francés,et al. Role of liver sinusoidal endothelial cells in liver diseases , 2021, Nature Reviews Gastroenterology & Hepatology.
[11] Jiang Ren,et al. Targeting TGFβ signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.
[12] Emma Minnee,et al. Translation initiation and its relevance in colorectal cancer , 2020, The FEBS journal.
[13] Tianrui Xu,et al. Eukaryotic translation initiation factors as promising targets in cancer therapy , 2020, Cell Communication and Signaling.
[14] O. Sansom,et al. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency , 2020, bioRxiv.
[15] J. Greenwood,et al. A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage , 2020, bioRxiv.
[16] U. Güller,et al. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases , 2020, BMC Cancer.
[17] Jing-Yuan Fang,et al. Comprehensive review of targeted therapy for colorectal cancer , 2020, Signal Transduction and Targeted Therapy.
[18] Kaoru Tanaka,et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. , 2019, The Journal of clinical investigation.
[19] K. Andrabi,et al. Eukaryotic initiation factor 4E (eIF4E): A recap of the cap‐binding protein , 2019, Journal of cellular biochemistry.
[20] Steven J. M. Jones,et al. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma , 2019, Clinical Cancer Research.
[21] Edward S. Kim,et al. Detection of NRG1 Gene Fusions in Solid Tumors , 2019, Clinical Cancer Research.
[22] L. Sequist,et al. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. , 2019, The oncologist.
[23] C. Jin,et al. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling , 2019, Journal of experimental & clinical cancer research : CR.
[24] David Bonekamp,et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. , 2018, Cancer discovery.
[25] L. Ellis,et al. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion , 2018, Molecular Cancer Research.
[26] Takami Sato,et al. Immunological aspect of the liver and metastatic uveal melanoma , 2017 .
[27] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[28] T. Ohkawara,et al. Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-β-Smad2 signaling in naïve helper T cells , 2017, Arthritis Research & Therapy.
[29] L. Ellis,et al. Endothelial cells activate the cancer stem cell‐associated NANOGP8 pathway in colorectal cancer cells in a paracrine fashion , 2017, Molecular oncology.
[30] Ying Zhou,et al. LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activation , 2017, PloS one.
[31] S. Steinberg,et al. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer , 2016, International journal of cancer.
[32] K. Kinzler,et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer , 2016, Nature Communications.
[33] R. Cuesta,et al. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer , 2016, Oncotarget.
[34] Y. Yarden,et al. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3 , 2016, Human Vaccines & Immunotherapeutics.
[35] Jingyuan Fang,et al. LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation , 2016, Journal of experimental & clinical cancer research : CR.
[36] L. Ellis,et al. A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling , 2016, Stem cells translational medicine.
[37] T. Ohkawara,et al. Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell lines , 2015, Oncotarget.
[38] I. Nagtegaal,et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.
[39] J. Greenwood,et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling (vol 499, pg 306, 2013) , 2013 .
[40] S. Markowitz,et al. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. , 2013, Cancer cell.
[41] L. Ellis,et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. , 2013, Cancer cell.
[42] S. Hanash,et al. Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women , 2012, Cancer Prevention Research.
[43] Philippe P Roux,et al. Regulation and function of the RSK family of protein kinases. , 2012, The Biochemical journal.
[44] H. Manji,et al. Evidence for Involvement of ERK, PI3K, and RSK in Induction of Bcl-2 by Valproate , 2009, Journal of Molecular Neuroscience.
[45] M. Ligtenberg,et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.
[46] Qiang Wang,et al. ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.
[47] Brian Raught,et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity , 2006, The EMBO journal.
[48] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[49] Walter Gilbert,et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene , 1997, Nature.
[50] K. Kinzler,et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.